Buy Rating on Pullback: Solid Top-Line Growth, Ingrezza Strength, and Crenessity Blockbuster Potential Support Long-Term Upside

William Blair analyst Myles Minter has maintained their bullish stance on NBIX stock, giving a Buy rating today.

Myles Minter has given his Buy rating due to a combination of factors, including solid top-line performance driven by Crenessity and a reassuring outlook for Ingrezza that aligns with market expectations. He views the planned salesforce expansion and anticipated midteens volume growth as key supports for Ingrezza’s continued competitive position versus Austedo, while also highlighting strong free cash flow and a robust life cycle strategy.

At the same time, Minter sees the recent share pullback as an attractive entry point despite near‑term noise around Crenessity prescription trends and the lack of formal product guidance. He expects broader commercial reach beginning in April to reignite new prescription growth in the back half of 2026 and underscores management’s confidence in Crenessity achieving blockbuster status, alongside a pipeline that should deliver meaningful catalysts over the longer term.

In another report released today, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $159.00 price target.